肠壁MRI T1弛豫时间估计用于评估儿童克罗恩病肠道炎症
前瞻性纳入新诊断回肠型克罗恩病患儿19例与健康对照15例,采用MOLLI序列测量末端回肠肠壁T1值;患儿T1值(中位1302 ms)较对照组(1159 ms)显著延长(p<0.001),生物制剂治疗后随时间下降(p=0.001),且与ESR、CRP、wPCDAI相关。
要点
- 新诊断回肠型克罗恩病患儿肠壁T1值较健康对照显著延长(中位1302 ms对1159 ms,p<0.001)。
- 生物制剂治疗后肠壁T1值随时间下降(p=0.001),基线至6周降幅最大(p<0.001)。
- T1值与ESR(ρ=0.35;p=0.01)、CRP(ρ=0.34;p=0.02)、wPCDAI(ρ=0.39;p=0.005)相关。
核心结论
- 新诊断回肠型克罗恩病患者肠壁T1值异常升高,并随药物治疗而下降。
研究设计与样本
- 前瞻性研究,纳入新诊断回肠型克罗恩病患者19例(男12例,中位年龄14岁)与健康对照15例(男7例,中位年龄17岁),2018年12月至2021年10月招募;患者于基线及生物制剂治疗6周、6个月时行研究性肠道MRI,对照仅行单次MRI;采用改良Look-Locker反转恢复(MOLLI)序列行末端回肠原生T1弛豫测量,在扫描仪生成的参数图上测量T1值,每次访视记录肠道炎症临床标志物。
关键影像表现/征象
- 克罗恩病患者肠壁T1值(中位1302 ms)较健康对照(中位1159 ms)显著延长(p<0.001)。
- 克罗恩病患者治疗后T1值随时间变化(p=0.001),基线至6周降幅最大(p<0.001)。
诊断标准与关键数值
- 肠壁T1值在克罗恩病患者中位1302 ms,健康对照中位1159 ms(p<0.001)。
- T1值与ESR相关(ρ=0.35;p=0.01)、与CRP相关(ρ=0.34;p=0.02)、与wPCDAI相关(ρ=0.39;p=0.005)。
- T1值与血清白蛋白(ρ=-0.28;p=0.051)及粪便钙卫蛋白(ρ=0.07;p=0.63)无显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare bowel wall T1 relaxation estimates in young patients with newly diagnosed ileal CD to healthy control participants, characterize their change over time in response to biologic medical therapy, and evaluate their associations with clinical markers of intestinal inflammation.
MATERIALS AND METHODS: Patients with newly diagnosed ileal CD and healthy control participants were prospectively recruited between December 2018 and October 2021. Patients underwent research MRI examinations of the bowel at baseline and at 6-weeks and 6-months into biologic medical treatment; control participants underwent single MRI examinations. MRI examinations included native T1 relaxometry of the terminal ileum using a modified Look-Locker inversion recovery (MOLLI) sequence. T1 estimates were measured on scanner-generated parametric maps. Clinical markers of intestinal inflammation were recorded at each visit. Group differences were assessed using the Mann-Whitney U test; the Friedman test was used to assess longitudinal changes in T1 estimates. Spearman correlation was used to evaluate associations between T1 estimates and inflammatory markers.
RESULTS: Nineteen participants with CD (12 males; median age 14 years) and 15 control participants (7 males; median age 17 years) were included in the study. Bowel wall T1 estimates in CD patients (median 1302 ms) were significantly longer compared to control participants (median 1159 ms) (p < 0.001). In CD patients, T1 estimates changed over time after treatment (p = 0.001), with largest reductions between baseline and 6-weeks (p < 0.001). T1 estimates correlated with inflammatory markers, including erythrocyte sedimentation rate (ρ = 0.35; p = 0.01), c-reactive protein level (ρ = 0.34; p = 0.02), and weighted Pediatric Crohn's Disease Activity Index (ρ = 0.39; p = 0.005). T1 estimates did not correlate with serum albumin (ρ = - 0.28; p = 0.051) and fecal calprotectin (ρ = 0.07; p = 0.63).
CONCLUSION: Bowel wall T1 estimates are abnormally increased in newly diagnosed ileal CD patients and decrease in response to medical therapy.
引用
- Mahalingam, Tkach, Denson, et al. Bowel wall MRI T1 relaxation estimates for assessment of intestinal inflammation in pediatric Crohn's disease. Abdom Radiol (NY). 2022. PMID: 35657390. doi:10.1007/s00261-022-03560-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。